日期 | 股東名稱 | 披露原因 | 買入/賣出涉及 的股份數目 |
每股平均價 | 持有權益的 股份數目 |
佔已發行 股本(%) |
03/10/2023 | China Pharmaceutical Company Limited | 1710(L) | +500,000(L) | HKD4.503(L) | 822,130,000(L) | 27.68 |
29/09/2023 | China Pharmaceutical Company Limited | 1710(L) | +1,000,000(L) | HKD4.467(L) | 821,630,000(L) | 27.66 |
29/09/2023 | 曲繼廣 | 1113(L) | +1,000,000(L) | HKD4.467(L) | 1,103,638,000(L) | 37.16 |
28/09/2023 | China Pharmaceutical Company Limited | 1710(L) | +1,000,000(L) | HKD4.591(L) | 820,630,000(L) | 27.63 |
28/09/2023 | 曲繼廣 | 1113(L) | +1,000,000(L) | HKD4.591(L) | 1,102,638,000(L) | 37.13 |
07/09/2023 | China Pharmaceutical Company Limited | 1710(L) | +300,000(L) | HKD4.249(L) | 819,630,000(L) | 27.60 |
07/09/2023 | 曲繼廣 | 1113(L) | +300,000(L) | HKD4.249(L) | 1,101,638,000(L) | 37.09 |
05/09/2023 | 曲繼廣 | 1113(L) | +300,000(L) | HKD4.461(L) | 1,101,338,000(L) | 37.08 |
05/09/2023 | China Pharmaceutical Company Limited | 1710(L) | +300,000(L) | HKD4.461(L) | 819,330,000(L) | 27.59 |
25/08/2023 | UBS Group AG | 1305(L) | 2,260,000(L) | 310,038,288(L) | 10.44 | |
11/07/2023 | 曲繼廣 | 1101(L) | +370,000(L) | HKD4.593(L) | 1,101,038,000(L) | 37.07 |
07/07/2023 | 曲繼廣 | 1101(L) | +1,892,000(L) | HKD4.405(L) | 1,100,668,000(L) | 37.06 |
06/07/2023 | 曲繼廣 | 1113(L) | +1,000,000(L) | HKD4.460(L) | 1,098,776,000(L) | 37.00 |
06/07/2023 | China Pharmaceutical Company Limited | 1710(L) | +1,000,000(L) | HKD4.460(L) | 819,030,000(L) | 27.58 |
05/07/2023 | 曲繼廣 | 1113(L) | +1,000,000(L) | HKD4.802(L) | 1,097,776,000(L) | 36.96 |
05/07/2023 | China Pharmaceutical Company Limited | 1710(L) | +1,000,000(L) | HKD4.802(L) | 818,030,000(L) | 27.54 |
23/06/2023 | 曲繼廣 | 1113(L) | +650,000(L) | HKD4.936(L) | 1,096,776,000(L) | 36.93 |
23/06/2023 | China Pharmaceutical Company Limited | 1710(L) | +650,000(L) | HKD4.936(L) | 817,030,000(L) | 27.51 |
05/06/2023 | UBS Group AG | 1306(L) | 3,654,539(L) | 311,676,312(L) | 10.49 | |
31/05/2023 | China Pharmaceutical Company Limited | 1710(L) | +600,000(L) | HKD4.751(L) | 816,380,000(L) | 27.49 |
31/05/2023 | 曲繼廣 | 1113(L) | +600,000(L) | HKD4.751(L) | 1,096,126,000(L) | 36.91 |
09/05/2023 | 曲繼廣 | 1101(L) | +1,000,000(L) | HKD4.938(L) | 1,095,526,000(L) | 36.88 |
09/05/2023 | 曲繼廣 | 1113(L) | +1,000,000(L) | HKD5.022(L) | 1,094,526,000(L) | 36.84 |
09/05/2023 | China Pharmaceutical Company Limited | 1710(L) | +1,000,000(L) | HKD5.022(L) | 815,780,000(L) | 27.46 |
05/05/2023 | China Pharmaceutical Company Limited | 1710(L) | +1,000,000(L) | HKD5.237(L) | 814,780,000(L) | 27.43 |
05/05/2023 | 曲繼廣 | 1113(L) | +1,000,000(L) | HKD5.237(L) | 1,093,526,000(L) | 36.81 |
26/04/2023 | 曲繼廣 | 1113(L) | +500,000(L) | HKD5.511(L) | 1,092,526,000(L) | 36.75 |
26/04/2023 | China Pharmaceutical Company Limited | 1710(L) | +500,000(L) | HKD5.511(L) | 813,780,000(L) | 27.37 |
13/04/2023 | UBS Group AG | 1306(L) | 3,040,000(L) | 310,040,295(L) | 10.43 | |
11/04/2023 | China Pharmaceutical Company Limited | 1710(L) | +200,000(L) | HKD4.762(L) | 813,280,000(L) | 27.36 |
11/04/2023 | 曲繼廣 | 1113(L) | +200,000(L) | HKD4.762(L) | 1,092,026,000(L) | 36.74 |
06/04/2023 | 曲繼廣 | 1113(L) | +430,000(L) | HKD4.766(L) | 1,091,826,000(L) | 36.73 |
06/04/2023 | China Pharmaceutical Company Limited | 1710(L) | +430,000(L) | HKD4.766(L) | 813,080,000(L) | 27.35 |
04/04/2023 | 曲繼廣 | 1101(L) | +500,000(L) | HKD4.609(L) | 1,091,396,000(L) | 36.71 |
03/04/2023 | 曲繼廣 | 1113(L) | +400,000(L) | HKD4.595(L) | 1,090,896,000(L) | 36.70 |
03/04/2023 | China Pharmaceutical Company Limited | 1710(L) | +400,000(L) | HKD4.595(L) | 812,650,000(L) | 27.34 |
29/03/2023 | 曲繼廣 | 1101(L) | +500,000(L) | HKD4.198(L) | 1,090,496,000(L) | 36.68 |
29/03/2023 | 曲繼廣 | 1710(L) | +400,000(L) | HKD4.175(L) | 1,089,996,000(L) | 36.66 |
29/03/2023 | China Pharmaceutical Company Limited | 1710(L) | +400,000(L) | HKD4.175(L) | 812,250,000(L) | 27.32 |
1 2 3 |
備註: | (L) - 長倉:包括 (1) 持有股份;(2) 透過持有、沽出或發行金融合約,有權或有責任購買相關股份。 |
(S) - 短倉:包括 (1) 借入股份;(2) 透過持有、沽出或發行金融合約,有權或有責任沽出相關股份。 | |
(P) - 可供借出的股份 | |
即時報價更新時間為 22/11/2024 17:59 | |
港股即時基本市場行情由香港交易所提供; 香港交易所指定免費發放即時基本市場行情的網站 | |
新聞
股票
期貨期權
權證
ETF
A股
外匯黃金
加密貨幣
基金
MPF